2023 Fiscal Year Final Research Report
Development of precision medicine for the soft tissue sarcoma using PDOX mouse model
| Project/Area Number |
20K17991
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 56020:Orthopedics-related
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2024-03-31
|
| Keywords | 軟部肉腫 / 個別化医療 / PDOXモデル / 薬剤感受性 |
|---|
| Outline of Final Research Achievements |
In this study, we applied our newly developed "clinically relevant animal model," the Patient Derived Orthotopic Xenograft (PDOX) model mouse, to soft tissue sarcoma. We conducted drug sensitivity tests using drugs currently available in clinical practice. In the established seven PDOX models, the drug sensitivity of the standard treatment drug doxorubicin correlated with the therapeutic effect observed in clinical patients, demonstrating the utility of the mouse model. Additionally, in the sensitivity tests using currently available drugs, we identified drugs that showed greater efficacy than doxorubicin.
|
| Free Research Field |
骨軟部腫瘍
|
| Academic Significance and Societal Importance of the Research Achievements |
軟部肉腫は発生頻度の低い希少がんであり，さまざまな病理型の腫瘍が存在するため患者数の多い癌腫と比較して新規薬剤の有効性を大規模臨床試験で判定することが難しいた．我々が開発した患者臨床をより反映した患者由来組織同所性異種移植を用いた薬剤感受性試験により有効な薬剤を見出すことは軟部肉腫の個別化医療の開発につながる重要な一歩であると考える．
|
